Roivant Sciences Ltd.

ROIV ·Healthcare, Drug Manufacturers - General
Financial Statements Balance Sheet
Annual Quarterly

Balance Sheet

Line Item FY2026 FY2025 FY2024 FY2023 FY2022 FY2021 FY2020
Assets
Cash & Equivalents $1.42B $2.72B $6.49B $1.68B $2.06B $2.06B $2.27B
Accounts Receivable $53.5M $30.4M $3.9M
Inventory $35.3M $2.8M $0
Total Current Assets $5.17B $5.00B $6.73B $1.80B $2.15B $2.19B
Property, Plant & Equipment $12.0M $12.1M $15.3M $39.1M $25.9M $14.7M
Goodwill
Intangible Assets (Excl. Goodwill) $137.8M $144.9M $0
Total Assets $5.71B $5.44B $7.22B $2.39B $2.59B $2.59B
Liabilities
Accounts Payable $18.0M $23.7M $14.0M $37.8M $34.6M $20.6M
Total Current Liabilities $281.2M $149.4M $266.8M $272.4M $184.4M $219.0M
Long-Term Debt $430.6M $375.5M $210.0M $170.3M
Total Liabilities $416.3M $249.7M $774.0M $782.0M $523.7M $527.7M
Stockholders' Equity
Retained Earnings $-501.8M $116.1M $576.2M $-3.77B $-2.76B $-1.92B
Total Stockholders' Equity $4.53B $4.69B $5.97B $1.16B $1.66B $1.80B $2.09B